Chemically induced acute model of sarcosinemia in wistar rats
- 103 Downloads
In the present study, we developed an acute chemically induced model of sarcosinemia in Wistar rats. Wistar rats of 7, 14 and 21 postpartum days received sarcosine intraperitoneally in doses of 0.5 mmol/Kg of body weight three time a day at intervals of 3 h. Control animals received saline solution (NaCl 0.85 g%) in the same volume (10 mL/Kg of body weight). The animals were killed after 30 min, 1, 2, 3 or 6 h after the last injection and the brain and the blood were collected for sarcosine measurement. The results showed that plasma and brain sarcosine concentrations achieved levels three to four times higher than the normal levels and decreased in a time-dependent way, achieving normal levels after 6 hours. Considering that experimental animal models are useful to investigate the pathophysiology of human disorders, our model of sarcosinemia may be useful for the research of the mechanisms of neurological dysfunction caused by high tissue sarcosine levels.
KeywordsSarcosinemia Metabolic disease Animal model Sarcosine
This work was supported by the research grants from Programa de Núcleos de Excelência (PRONEX), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) and FINEP Rede Instituto Brasileiro de Neurociência.
- Bayer SA, Altman J (1995) Principles of neurogenesis, neuronal migration, and neural circuit formation. In: Paxinos G (ed) The rat nervous system, 3rd edn. Academic Press, San Diego, pp. 1079–1098Google Scholar
- Cicero TJ, Adams ML, Giordano A, Miller BT, O’Connor L, Nock B (1990) Influence of morphine exposure during adolescence on the sexual maturation of male rats and the development of their offspring. J Pharmacol Exp Ther 256:1086–1093Google Scholar
- Enesco M, Leblond CP (1962) Increase in cell number as a factor in the growth of the organs and tissues of the young male rat. J Embryol Exp Morphol 10:530–562Google Scholar
- Gemelli T, de Andrade RB, Rojas DB, Bonorino NF, Mazzola PN, Tortorelli LS, Funchal C, Dutra-Filho CS, Wannmacher CMD (2013) Effects of b-alanine administration on selected parameters of oxidative stress and phosphoryltransfer network in cerebral cortex and cerebellum of rats. Mol Cell Biochem 80:161–170. doi: 10.1007/s11010-013-1669-8 CrossRefGoogle Scholar
- Harding CO, Williams P, Pflanzer DM, Colwell RE, Lyne PW, Wolff JA (1992) SAR: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis. Proc Nat Acad Sci. 89: 2644–2648Google Scholar
- Kimmel CA (1998) Current approaches. In: Slikker WJr, Chang LW (ed) Developmental neurotoxicology, Academic Press, San Diego, pp 675–685Google Scholar
- Krinke G, Eisenbrandt DL (1994) In: Mohr U, Dungworth DL, Capen CC (eds) Pathobiology of the aging rat. ILSI Press, Washington DC, pp. 3–9Google Scholar
- Ross EM, Gilman AG (1990) Pharmacodynamics: mechanism of drug action and the relationship between drug concentration and effect. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 8rd edn. Macmillan Publishing Company, New York chapter 2Google Scholar
- Scott CR (2001) Sarcosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. The McGraw-Hill Companies, New York, pp. 2057–2063Google Scholar
- Socala K, Nieoczym D, Rundfeldt C, Wlaz (2010) Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models. Pharmacol Rep 62: 392–397Google Scholar